What do systematic reviews say?

Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT

Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) may leads to lower steroid use compared with WBRT (low certainty).

• Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases 2017 · Cochrane Headline outcomes only
  RR 0.64 [0.42, 0.97]
  1 study · 118 participants
  Low

Intervention not reported

The intervention showed no clear difference in overall survival (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  HR 1.07 [0.81, 1.43]
  2 studies · 1851 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in recurrence‐free survival (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  HR 1.23 [0.96, 1.58]
  2 studies · 1851 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in direct surgical morbidity (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  RR 1.93 [0.79, 4.71]
  2 studies · 1922 participants
  Moderate

Intervention not reported

The intervention probably leads to higher surgery‐related systemic morbidity (moderate certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  RR 3.72 [1.04, 13.27]
  2 studies · 1922 participants
  Moderate

Intervention not reported

The intervention leads to higher lymphoedema or lymphocyst (high certainty).

• Lymphadenectomy for the management of endometrial cancer 2017 · Cochrane Headline outcomes only
  RR 8.39 [4.06, 17.33]
  2 studies · 1922 participants
  High

Intervention not reported

The intervention showed no clear difference in overall Survival (median (low certainty).

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  HR 1.11 [0.83, 1.48]
  5 studies · 663 participants
  Low

Intervention not reported

The intervention showed no clear difference in progression free survival (low certainty).

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  HR 0.76 [0.53, 1.1]
  2 studies · 378 participants
  Low

Intervention not reported

The intervention may leads to lower any intracranial disease progression at 1 year (low certainty).

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  RR 0.46 [0.35, 0.6]
  4 studies · 304 participants
  Low

Intervention not reported

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 209 participants
  Low

Intervention not reported

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 436 participants
  Low

Intervention not reported

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 568 participants
  Low

Intervention not reported

The intervention probably leads to lower 5‐ year OS (moderate certainty).

• Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
  HR 0.75 [0.57, 0.99]
  2 studies · 620 participants
  Moderate

Intervention not reported

The intervention probably leads to lower 5‐year PFS (moderate certainty).

• Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
  HR 0.74 [0.59, 0.92]
  2 studies · 620 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in 5‐year OS (stage III) (moderate certainty).

• Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
  HR 0.76 [0.57, 1.02]
  2 studies · 514 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in 5‐year PFS (stage III) (moderate certainty).

• Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
  HR 0.81 [0.63, 1.05]
  2 studies · 514 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).

• Adjuvant chemotherapy for advanced endometrial cancer 2014 · Cochrane Headline outcomes only
  HR 0.9 [0.69, 1.17]
  1 study · 552 participants
  Moderate

Summary of findings: EBRT vs no EBRT

Summary of findings: EBRT showed no clear difference in death from all causes compared with no EBRT (moderate certainty).

• Adjuvant radiotherapy for stage I endometrial cancer 2012 · Cochrane Headline outcomes only
  HR 0.99 [0.82, 1.2]
  2628 participants
  Moderate

Summary of findings: EBRT vs no EBRT

Summary of findings: EBRT leads to lower locoregional recurrence compared with no EBRT (high certainty).

• Adjuvant radiotherapy for stage I endometrial cancer 2012 · Cochrane Headline outcomes only
  HR 0.36 [0.25, 0.52]
  2965 participants
  High

Summary of findings: EBRT vs no EBRT

Summary of findings: EBRT leads to higher severe acute toxicity compared with no EBRT (high certainty).

• Adjuvant radiotherapy for stage I endometrial cancer 2012 · Cochrane Headline outcomes only
  RR 4.68 [1.35, 16.16]
  1328 participants
  High